Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q96Q45
UPID:
TM237_HUMAN
Alternative names:
Amyotrophic lateral sclerosis 2 chromosomal region candidate gene 4 protein
Alternative UPACC:
Q96Q45; B4E1R8; B4E2R8; E9PAR8; E9PBF8; E9PG24; E9PGX0; Q53TS9; Q53TT2; Q7Z3B6; Q8IZ18; Q8NBF8; Q96CY1
Background:
Transmembrane protein 237, also known as Amyotrophic lateral sclerosis 2 chromosomal region candidate gene 4 protein, plays a crucial role in the formation and function of primary cilia. It is a key component of the transition zone in primary cilia, essential for ciliogenesis, the process by which cilia are formed.
Therapeutic significance:
Transmembrane protein 237 is implicated in Joubert syndrome 14, a disorder marked by severe intellectual disability and distinctive neuroradiological features. Understanding the role of Transmembrane protein 237 could open doors to potential therapeutic strategies for this and related ciliopathies.